CF
TERN

Corebridge Financial’s Terns Pharmaceuticals TERN Stock Holding History

Corebridge Financial’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34,440
Closed -$95.1K – 2509
2025
Q1 		$95.1K Sell
34,440
-511
-1% -$2.09K ﹤0.01% 2464
2024
Q4 		$194K Buy
34,951
+4,169
+14% +$28.2K ﹤0.01% 2205
2024
Q3 		$257K Sell
30,782
-190
-0.6% -$1.56K ﹤0.01% 2076
2024
Q2 		$211K Buy
+30,972
New +$188K ﹤0.01% 2161

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Corebridge Financial's TERN Position: Q2 2025 in Review

Corebridge Financial sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 34,440 shares — an estimated $95.1K sold.

Corebridge Financial first reported a position in TERN in Q2 2024 and held it in 4 quarters. The position peaked at $257K in Q3 2024. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Corebridge Financial reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 34,440 Terns Pharmaceuticals shares in Q2 2025, an estimated $95.1K.
  • Corebridge Financial first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Terns Pharmaceuticals position peaked at $257K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.